Suspension - Jiangte Motor's actual controller is planning a change in company control, leading to stock suspension [1] - Sinochem Equipment is planning to issue shares to acquire 100% equity of multiple companies, resulting in stock suspension [1] Private Placement - Huafeng Technology plans to raise no more than 1 billion yuan through private placement for the expansion of high-speed line module projects [2] Equity Transfer - Longxin General's state-owned shareholder is transferring 15.52% of the company's shares from Yufu Capital without compensation [3] - Yunda Technology's controlling shareholder intends to transfer 10% of the company's equity to Zhixiang Dahang at a price of 9.01 yuan per share [4] External Investment and Daily Operations - Fuxin Technology's Micro TEC product has reached industry-leading performance and has passed product verification from a major telecommunications company, achieving bulk supply [5] - Dongfang Precision has signed a strategic cooperation agreement with Leju Robotics [6] - Hongxin Technology has signed a technology development and parts procurement contract with a leading domestic flying car company in the low-altitude economy [7] - Fuwei Co., Ltd. received a project notification from a well-known luxury brand manufacturer, with a project lifecycle expected to last 6-7 years and total sales amounting to 4.9 billion yuan [7] - Rainbowsoft Technology's actual controller proposed a cash dividend of no less than 60% of net profit for the 2025 interim period [8] - Samsung Medical's subsidiary won a transformer procurement framework contract in Brazil worth approximately 341 million yuan [9] - Chuling Information's subsidiary signed a framework contract for intelligent computing network integration [9] - Baotai's BAT4406F injection has received approval for clinical trials [9] - Junxin Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange [9] - Dongfang Precision has signed a strategic cooperation agreement with Leju Robotics [10] - Daikin Heavy Industry signed a 430 million yuan contract for offshore wind power monopile foundations in Europe [11] - Kunming Pharmaceutical Group's subsidiary obtained a drug registration certificate for carbonic acid sevelamer dry suspension [12] - Xiechuang Data has initiated preparations for overseas share issuance and application for listing on the Hong Kong Stock Exchange [13] - Health元's restructured anti-IL-17A/F humanized monoclonal antibody injection's phase III clinical trial has reached its primary research endpoint [14] - Beilu Zhikong plans to invest 600 million yuan to build an intelligent driving industrialization base for mining [15] - Jucan Optoelectronics reported a net profit of 117 million yuan for the first half of the year, a year-on-year increase of 3.43%, and plans a 10-for-4.5 stock split [16] Performance Changes - Jinghe Integration expects a net profit of 260 million to 390 million yuan for the first half of 2025, a year-on-year increase of 39.04% to 108.55% due to increased product sales and high capacity utilization [10] - Baismei anticipates a net profit of 33.11 million to 44.42 million yuan for the first half of 2025, a year-on-year increase of 100.07% to 168.38% driven by product structure optimization and international trade channel development [11] - Changying Tong expects a net profit of 26.12 million to 31.92 million yuan for the first half of 2025, a year-on-year increase of 72.12% to 110.33% due to significant growth in optical fiber device deliveries [12] - Mankun Technology expects a net profit of 60 million to 70 million yuan for the first half of 2025, a year-on-year increase of 53.98% to 79.64% as the company optimizes product and customer structure [13] - Canqin Technology anticipates a net profit of 51.3 million to 55.3 million yuan for the first half of 2025, a year-on-year increase of 50.14% to 61.85% due to new product development and market expansion [14] - Aerospace Huanyu expects a net profit of approximately 34.38 million yuan for the first half of 2025, a year-on-year increase of 50.59% driven by revenue growth and changes in product sales structure [15] - Keda Li expects a net profit of 750 million to 820 million yuan for the first half of 2025, a year-on-year increase of 15.73% to 26.53% due to increased sales of new energy vehicles [16] - Honghua Digital expects a net profit of 240 million to 260 million yuan for the first half of 2025, a year-on-year increase of 19.90% to 29.89% as traditional printing equipment transitions to digital printing [17] - Yangjie Technology anticipates a net profit of 552 million to 637 million yuan for the first half of 2025, a year-on-year increase of 30% to 50% due to growth in the semiconductor industry [18] - Haitai Ruisheng expects a net profit of 2.944 million to 4.416 million yuan for the first half of 2025, a year-on-year increase of 607.01% to 960.52% driven by rapid development in AI technology [19] - Zhongshi Technology expects a net profit of 116 million to 129 million yuan for the first half of 2025, a year-on-year increase of 85.01% to 105.75% due to recovery in consumer electronics market demand [20]

昆药集团（600422）公告，全资子公司昆明贝克诺顿制药有限公司近日收到国家药监局核准签发的碳酸 司维拉姆干混悬剂《药品注册证书》。碳酸司维拉姆干混悬剂用于控制正在接受透析治疗的慢性肾脏病 (CKD)成人患者的高磷血症，以及控制血清磷≥1.78mmol/L但并未进行透析的慢性肾脏病成人患者的高 磷血症。公司对碳酸司维拉姆干混悬剂累计研发投入约1318万元人民币。 ...